Summit cut to Underperform at Bernstein on R&D capabilities

Bernstein downgraded Summit Therapeutics (SMMT) to Underperform, citing concerns over its R&D capabilities after the FDA declined to approve its lead asset, ivonescimab, developed with Akeso (AKESF).

Original reporting
Published Nov 18, 2026, 5:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 5:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Summit cut to Underperform at Bernstein on R&D capabilities — source image
Decision brief

The 30-second read

$SMMTBearishMed
01

Why it matters

The downgrade may trigger short-term price decline, but longer-term upside remains if the company secures alternative pathways.

02

Market read

Analyst downgrade based on FDA rejection is a fresh catalyst for Summit Therapeutics, likely affecting its stock price and potentially influencing sentiment in the broader biotech sector.

03

What to watch

Potential upcoming data from partner Akeso or alternative indications for ivonescimab.

Relevance 7/10Novelty 6/10Timing: pre-market today

Background

Summit Therapeutics is a clinical-stage biotech developing ivonescimab with partner Akeso. The FDA declined approval, prompting analyst concerns.

Company-level read

Ticker impact

$SMMTBearishMedium confidence
Context

Bernstein downgraded Summit Therapeutics to Underperform due to concerns over its R&D after FDA rejection of ivonescimab.

Expected impact

downward pressure as investors price in the downgrade

Evidence & confidence

Analyst downgrade with specific R&D concerns is a fresh, material catalyst for a small-cap biotech.

Market effects

May weigh on other small-cap biotech stocks awaiting FDA decisions.

Limited to U.S. biotech sector; no broader regional effect.

Low; impact confined to Summit and peers.

Counterpoint

If the FDA decision is appealed or additional data emerges, the downgrade could be premature.

Key entities

  • Summit Therapeutics

    Biotech firm developing ivonescimab.

  • Akeso

    Chinese partner in ivonescimab development.

Related articles

$SMMTMedAI 8/10

FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK

FDA rejected Summit Therapeutics' ivonescimab for lung cancer, citing insufficient benefits. Sellas Life Sciences' cancer vaccine showed 41% reduced death risk in a Phase 3 trial. GSK's Nelkarmi, acquired via Nuvalent buyout, gained FDA approval for lung cancer. AstraZeneca's gefurulimab was approved for myasthenia gravis. Eli Lilly partnered with Stipple Bio for cancer drugs, potentially worth $5.9B. Biogen invested $32M in Trimtech for neurodegenerative disease treatments.

$SMMTMed

Summit Therapeutics Plans Global Phase III HARMONi-10 Trial of Ivonescimab

Summit Therapeutics (SMMT) plans a global Phase III trial (HARMONi-10) for ivonescimab vs. durvalumab in treating unresectable Stage III non-small cell lung cancer. The trial, set to begin in Q4 2026, aims to study patients without disease progression after initial treatment, with progression-free survival as the primary endpoint. This is Summit's sixth Phase III ivonescimab study and fourth in this cancer type, according to the company.

$SMMTMed

Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase III HARMONi-10 Study in Unresectable Stage III Non-Small Cell Lung…

Summit Therapeutics Inc. (SMMT) filed an SEC Form 8-K — Other Events. Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase III HARMONi-10 Study in Unresectable Stage III Non-Small Cell Lung Cancer Global Registration-Enabling Study to Evaluate Ivonescimab Versus Durvalumab as Consolidation Therapy Following Concurre

$SMMTMedAI 8/10

Summit starts phase 3 trial of ivonescimab in lung cancer

Summit Therapeutics (NASDAQ: SMMT) launched a Phase III trial (HARMONi-10) for ivonescimab in lung cancer, comparing it to durvalumab. The trial aims to evaluate progression-free survival as the primary endpoint, with global site activations expected in Q4 2026. Ivonescimab, a PD-1 x VEGF bispecific antibody, is not approved in the U.S. or Europe but has marketing authorization in China. Over 5,000 patients have been treated in clinical studies globally, and over 100,000 in China.